TENDER NO. BMSIC/DRUGS/18-04

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name _Medopharm _____ Total Number of Pages Submitted in bid documents_____

Sl. No	SBD clause serial No	Descrption of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	**Tender Fee (Non –Refundable) of Rs 10,000/- in form of Demand Draft** drawn in Favor of "Managing Director, Bihar Medical Services and Infrastructure Corporation Limited" payable at Patna. This fee is payable only once for one tender irrespective of items contained therein.	yes	1	yes	
2	3.(b)	Bidder are required to submit **Earnest Money Deposit in the form of Demand Draft / Bank Guarantee** drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna as follows:- Upto 5 drugs- Rs1,00,000/- (One Lakh only), for 6 to 10 drugs- Rs 2,00,000/- (Two Lakh only), for 11 to 20 drugs- Rs 3,00,000/-(Three Lakh only) and for More than 20 drugs Rs 5,00,000/- (Five Lakh only)	yes	67-71	yes	
3	3.(c)	Documentary evidence of the **constitution of the company/ firm/ Proprietorship such as Memorandum and Articles of Association, Partnership Deed** etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	yes	17-19	yes	
4	3.(d)	The **details of Bidder** Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	yes	87	yes	
5	3.(e)	**Power of Attorney or Resolution of Board** by which the **authorised signatory** has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. **Format to be used.**	yes	4	yes	
6	3.(l)	Copies of the **Audited Balance Sheet and Profit and Loss statement** showing details of their annual average turnover not less than **25 Crores** for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). **Self-attested copies** are to be submitted.	yes	72-80	yes	

Chandan Kumar
7/7/18

7	3.(m)	Copy of **Income Tax Return for any three of last four Consecutive Assessment years** should be submitted **(self-attested).**	**yes**	**57-59**	**yes**	
8	3.(p)	**Copy of PAN Card of the bidder company should be submitted (self-attested).**	**yes**	**5**	**yes**	
9	3.(q)	**Copy of certificate of valid Sales Tax/VAT and GST registration of the bidder company should be submitted (self-attested).**	**yes**	**62-64**	**yes**	

Chandan Kumar Jha
14/7/18

TENDER NO. BMSIC/DRUGS/18-04

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids ---

Company Name - Medopharma - Total Number of Pages Submitted in bid documents - 127

Sl. No	SBD Clause serial No	Descrption of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The **details of Bidder** Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	87	Yes	
2	3.(e)	**Power of Attorney or Resolution of Board** by which the **authorised signatory** has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. **Format to be used.**	NA	---	---	
3	3.(f)	Minimum **three years old valid Manufacturing License of the product quoted with latest license renewal certificate**.	Yes	37,38, 54, 56	Yes	
4		**Approved product list as per the license issued for quoted drugs for minimum three years.**	Yes	36 -24	Yes	
5		**Manufacturing License** along with approved product list must be **valid till the last date of the submission of tender.**	Yes	37, 38, 36 - 24	Yes	
6		In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.	NA	NA	NA	
7		**Market standing certificate & Manufacturing certificate** issued by the Licensing Authority as a Manufacturer **for each drug quoted** for the **last 3 years** (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation).	Yes	16 to 9	Yes	
8		If permission in **Form 46 (For manufacturers) / Form 45 (For Importers) from DCGI** has been obtained, then the **3 years manufacturing/ Import & Market standing clause will be relaxed**. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.	NA	NA	NA	

14/7/18

9		For **all regulated products,** the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	**NA**	**NA**	**NA**	
10		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable	**NA**	**NA**	**NA**	
		NOTE: Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	**NA**	**NA**	**NA**	
11	**3.(g)**	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	**NA**	**NA**	**NA**	
12	**3.(h)**	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. **Self-attested copies** are to be submitted.	**Yes**	**16 to 9**	**Yes**	
13	**3.(i)**	Non Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted. It should be not more than one year old. **Self-attested copies** are to be submitted. For Surgicals In case of Non-Drug item "the bidder shall submit an affidavit on Non-Judicial stamp paper stating that the quoted product is not covered under Drugs & Cosmetics Act."	**Yes**	**6**	**Yes**	**(i) Certificate was issued for the Participation Tender floated by Employees state insurance corporation parchdeep Bhawan, C.L.G Road, New Delhi**
14	**3.(j)**	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule-'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. **Self-attested copies** are to be submitted.	**Yes**	**66**	**Yes**	

14/7/18

15	**3.(k)**	**Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department** highlighting the **quoted product** section. **Self-attested copies** are to be submitted. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production(Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/Evidence of import in items of said product with quantity details.	**Yes**	**20, 22, 23**	**Yes**	
16	**3.(n)**	**The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.**	**Yes**	**8**	**Yes**	Whether Blacklisted or not **Not Blacklisted as per the affidavit attached**
17	**3.(o)**	**List of item quoted in prescribed format as per Annexure-III duly signed.**	**Yes**	**2 to 3**	**Yes**	
18	**5.(k)**	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per **Annexure-IV.**	**Yes**	**85 to 86**	**Yes**	
19	**5.(l)**	**Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.**	No	-	-	**Not atteched with the provided documents**
20	**7.(c)**	**Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.**	Yes	4	Yes	
21	**10.(c)**	**If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.**	Yes	61	Yes	
22	**Corrigendum point**	**A Notarized affidavit on a Rs 100/- Non-Judicial Stamp Paper representing that the offered price is the lowest price as compared to the Rates provided to their respective Distributors/ Dealers/ Wholesalers/ Carrying and Forwarding Agents/ Authorized depot sales point in the State of Bihar.**	Yes	88	Yes	

14/7/18

TENDER NO. BMSIC/DRUGS/18-04

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name :- MedoPharma **Total number of pages submitted in bid documents - 127**

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	First Approval	Approved Upto	Approved in Brand /Generic Name	
1	3	Albendazole Tablet IP	Albendazole Tablet IP	400 mg	400 mg	10 x 10	Not Mentioned	Tablet	Tablet	26.06.2000	31.12.2021	Generic	Yes Product permission date on manufacturing and Marketing certificate is different from approved product lists renewed for the period from 01.01.2017 to 31.12.2021 (Page -16, 35)
2	19	Atenolol Tablets IP	Atenolol Tablets IP	50 mg	50 mg	10x14	Not Mentioned	Tablet	Tablet	26.06.2000	31.12.2021	Generic	Yes Product permission date on manufacturing and Marketing certificate is different from approved product lists renewed for the period from 01.01.2017 to 31.12.2021 (Page -14, 34)
3	24	Azithromycin Tablets IP	Azithromycin Tablets IP	250 mg	250 mg	10 x 10	Not Mentioned	Tablet	Tablet	15.08.2008	31.12.2021	Generic	Yes
4	25	Azithromycin Tablets IP	Azithromycin Tablets IP	500 mg	500 mg	10 x 10	Not Mentioned	Tablet	Tablet	15.08.2008	31.12.2021	Generic	Yes
5	41	Carbamazepine Tablets IP	Carbamazepine Tablets IP	200 mg	200 mg	10 x 10	Not Mentioned	Tablet	Tablet	26.06.2000	31.12.2021	Generic	Yes
6	71	Domperidone Tablets IP	Domperidone Tablets IP	10mg	10mg	10x10	Not Mentioned	Tablet	Tablet	20.10.2015 (Not fullfill the NIT criteria of Minimum three years)	31.12.2021	Generic	Yes Product permission date on manufacturing and Marketing certificate is different from approved product lists renewed for the period from 01.01.2017 to 31.12.2021 (Page - 14 , 32)

14/7/18

7	88	Frusemide Tablet IP	Frusemide Tablet IP	40 mg	40 mg	10 x 10	Not Mentioned	Tablet	Tablet	25.06.2011	31.12.2021	Generic	**Yes Product permission date on manufacturing and Marketing certificate is different from approved product lists renewed for the period from 01.01.2017 to 31.12.2021 (Page - 13, 31)**
8	119	Levofloxacin Tablet IP	Levofloxacin Tablet IP F/C	500 mg	500 mg	10 x 10	Not Mentioned	Tablet	Tablet	25.06.2011	31.12.2021	Generic	**Yes Product permission date on manufacturing and Marketing certificate is different from approved product lists renewed for the period from 01.01.2017 to 31.12.2021 (Page - 15, 30)**
9	121	Levocetrizine Dihydrochloride IP	Levocetrizine Tablet IP 5 mg F/C	5mg	5mg	10x10	Not Mentioned	Tablet	Tablet	7.10.2008	31.12.2021	Generic	Yes
10	176	Phenytoin Sodium Tablet IP	Phenytoin Sodium Tablet IP	100 mg	100 mg	100 Tablets packed in bottle	Not Mentioned	Tablet	Tablet	7.09.2001	31.12.2021	Generic	Yes

14/7/18

TENDER NO. BMSIC/DRUGS/18-04

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name- Medopharma **Total number of pages submitted in bid documents- 127**

Sheet for verification of licence details

Sl. No	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	3	Albendazole Tablet IP	Form -25	KTK/25/445/2000	NA	NA	26.06.2000	31.12.2021	24.03.2018	23.03.2019
2	19	Atenolol Tablets IP	Form -25	KTK/25/445/2000	NA	NA	26.06.2000	31.12.2021	24.03.2018	23.03.2019
3	24	Azithromycin Tablets IP	Form -28	KTK/28/313/2000	NA	NA	15.08.2008	31.12.2021	24.03.2018	23.03.2019
4	25	Azithromycin Tablets IP	Form -28	KTK/28/313/2000	NA	NA	15.08.2008	31.12.2021	24.03.2018	23.03.2019
5	41	Carbamazepine Tablets IP	Form -25	KTK/25/445/2000	NA	NA	26.06.2000	31.12.2021	24.03.2018	23.03.2019
6	71	Domperidone Tablets IP	Form -25	KTK/25/445/2000	NA	NA	20.10.2015	31.12.2021	24.03.2018	23.03.2019
7	88	Frusemide Tablet IP	Form -25	KTK/25/445/2000	NA	NA	25.06.2011	31.12.2021	24.03.2018	23.03.2019
8	119	Levofloxacin Tablet IP	Form -25	KTK/25/445/2000	NA	NA	25.06.2011	31.12.2021	24.03.2018	23.03.2019
9	121	Levocetrizine Dihydrochloride IP	Form -25	KTK/25/445/2000	NA	NA	07.10.2008	31.12.2021	24.03.2018	23.03.2019
10	176	Phenytoin Sodium Tablet IP	Form -25	KTK/25/445/2000	NA	NA	07.09.2001	31.12.2021	24.03.2018	23.03.2019

Note:-Assisted in technical evaluation in reference to letter No-559(15), dated 26.6.2018 on the basis of documents provided by BMSICL in checklist-II, III & IV. Provided checklist compiled with due deligence and care. Inspite, some inadvertent discreprencies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discrepencies are observed for rectification.

14/7/18